Skip to main content

Table 1 Baseline characteristics

From: The relationship between synovitis quantified by an ultrasound 7-joint inflammation score and physical disability in rheumatoid arthritis – a cohort study

  Total (N = 185) Incident RA (N = 46) Prevalent RA (N = 139) P value
Female (%) 76.8 69.6 79.1 0.066
Age (years) 55.2 (14.0) 51.7 (12.6) 56.4 (14.2) <0.001*
Disease duration (years) 6.3 (7.7) 0.8 (0.7) 8.1 (8.1) <0.001*
Symptom duration (years) 7.3 (7.7) 1.5 (1.8) 9.2 (8.0) <0.001*
BMI 26.7 (4.5) 27.5 (5.2) 26.4 (4.3) 0.020*
RF+ (%) 47.2 43.5 48.5 0.466
ACPA+ (%) 62.9 58.7 64.3 0.952
CRP (mg/l) 7.6 (9.0) 10.5 (12.6) 6.6 (7.1) 0.354
DAS28-CRP 3.7 (1.5) 4.0 (1.5) 3.6 (1.5) 0.192
GSsynSS 6.91 (6.39) 7.70 (5.62) 6.65 (6.61) 0.255
PDsynSS 4.02 (5.20) 5.24 (5.95) 3.61 (4.87) 0.438
GStenSS 0.66 (1.15) 0.78 (1.18) 0.63 (1.14) 0.842
PDtenSS 0.68 (1.63) 0.80 (1.75) 0.63 (1.59) 0.402
Erosions score 1.18 (2.10) 0.46 (1.50) 1.42 (2.21) <0.001*
HAQ 0.77 (0.73) 0.88 (0.73) 0.74 (0.73) 0.896
Oral glucocorticoids (%) 43.8 41.3 44.6 0.607
csDMARDs (%) 87.0 69.6 92.8 <0.001*
  1. Values are mean (SD) if not stated otherwise. RA rheumatoid arthritis, BMI body mass index, RF rheumatoid factor, ACPA anti-citrullinated peptide antibodies, CRP C-reactive protein, DAS28 disease activity score in 28 joints, GS greyscale, PD power Doppler, syn synovitis, ten tenosynovitis, ES erosions score, SS sum-score, HAQ health assessment questionnaire, csDMARDS conventional synthetic disease-modifying anti-rheumatic drugs. *Significant at p < 0.05